4baseCare builds genomics-based cancer diagnostics and AI-led treatment support tools, and its latest 4baseCare funding update is a ₹128 crore Series B haul aimed at taking that model across more emerging markets. Cancer care still has a brutal data gap, especially for patients outside the datasets that shaped most precision oncology tools in the West. That’s the bet here. Founded in 2019 by Hitesh Goswami and Kshitij Rishi, the Bengaluru startup will use the fresh money to expand its genomics lab network and push harder on its oncology intelligence platform, OncoTwin.
What does 4baseCare actually sell?
4baseCare runs genomic tests that help oncologists match a cancer patient to more targeted treatment options. The workflow is direct: a hospital or doctor sends a tumor tissue sample, blood sample, or both. 4baseCare sequences the relevant material. Its platform identifies actionable mutations and biomarkers. It also flags resistance signals and related evidence. Then the oncologist gets a report built for treatment decisions rather than a raw genomics dump.
The product stack is wider than the source article suggests. Its TARGT First panel covers 92 commonly mutated genes for faster frontline decisions. TARGT Indiegene goes much deeper with a 1,212-gene panel. It includes markers such as tumor mutational burden, microsatellite instability, homologous recombination deficiency, gene fusions, and rare variants. At the top end, TARGT Absolute uses whole-exome profiling across roughly 20,000 genes.
Then there’s SoLiQ. Instead of treating tissue biopsy, liquid biopsy, and germline testing as separate jobs with separate reports, 4baseCare combines them into one analysis. That matters because cancer changes over time, tissue can be limited or stale, and blood-based ctDNA can reveal evolution or resistance that a single archived sample might miss. In plain English: fewer blind spots. Less manual stitching together of three different reports.
OncoTwin sits on top of that diagnostics layer. It doesn’t just show mutations, it tries to find “digital twins” — patients with similar clinical and genomic profiles — then summarizes treatment journeys, outcomes, match scores, and evidence quality for doctors in real time. It also supports molecular tumor board review with an integrated case workspace. That makes this more than a testing company.
Who built 4baseCare and why did investors back it?
The founding story
4baseCare was started by Hitesh Goswami and Kshitij Rishi with a specific thesis: cancer biology isn’t uniform across populations, but a lot of precision oncology still leans on datasets that underrepresent patients from India and other emerging markets. That’s not a branding line. It’s the company’s operating logic — build local genomics infrastructure, generate more relevant clinico-genomic data, and use that data to improve treatment decisions.
Why the founders fit this market
Goswami looks like the domain founder in the pair. He has more than 20 years across pharma drug discovery, genomics, and precision medicine, and earlier worked in high-throughput screening at Piramal Life Sciences. Before 4baseCare, he also co-founded Bionivid Technology, a genomics IT company built around data processing, storage, analytics, and training. That background matters because 4baseCare is a blend of diagnostics, data engineering, and oncology workflow.
Rishi brings the operator side. He’s an XLRI alumnus who held leadership roles at Deloitte and GE, and at 4baseCare he has handled partnerships and operations. He’s also led patient engagement and hospital network building. That’s useful because genomics startups don’t scale on software alone. They scale through logistics, clinician trust, lab operations, and repeat institutional relationships.
What they’ve already built
Bionivid is the clearest prior execution signal here because it shows Goswami was already working on genomics infrastructure problems before 4baseCare existed. Rishi’s earlier entrepreneurial experience plus large-company operating roles help explain why 4baseCare has pushed into cross-border lab expansion instead of staying a single-city testing outfit. It’s not flashy. But it’s credible.
Traction, labs, and hospital links
This isn’t a pre-product story. 4baseCare is already live and runs laboratories in India, Dubai, Nepal, and the Philippines. It wants to enter 8 to 10 more countries over the next 12 to 18 months. It’s also extending an in-hospital genomics lab model through partnerships with institutions including AIIMS Jammu, Max Healthcare, and Shankara Hospital. The company currently processes about 1,500 genomic tests a month. It expects that figure to rise to 8,000 to 10,000 a month as the network expands.
The 4baseCare funding details
The fresh tranche is ₹38 crore. growX Ventures and Infosys led it, and it takes total capital raised in this Series B cycle to ₹128 crore, or about $13.3 million. Earlier, 4baseCare had announced a ₹90 crore first close of the round from Ashish Kacholia, Lashit Sanghvi, and Yali Capital. The company will use the new money for global genomics lab expansion and deeper investment in OncoTwin.
There’s also some round-history context that helps. 4baseCare had previously raised ₹50 crore in Series A with Yali Capital and Infosys participating, and before that it disclosed a $2 million pre-Series A round backed by investors including growX Ventures. So this isn’t a sudden investor discovery. It’s a follow-on conviction story.
Competition and market positioning
Here’s the honest read: 4baseCare’s competition isn’t just other cancer startups raising money in India. Its real competition is fragmented pathology workflows, tissue-only testing, overseas genomic labs, and oncology teams still piecing together decisions from separate reports and literature searches. That’s slow and expensive. It’s often not designed for underrepresented populations.
Among newer players, OneCell Diagnostics is another Indian precision oncology name with a genomics-heavy approach, while startups like Everhope Oncology, MOC Cancer Care, and Oncare are attracting capital on the care-delivery side of the oncology stack rather than the diagnostics-and-decision-support layer where 4baseCare sits. That distinction matters. 4baseCare is trying to own the data and interpretation layer inside cancer treatment workflows, not build a chain of chemotherapy centers.
What does 4baseCare funding change next?
This 4baseCare funding round matters because genomics expansion is capital-heavy in a way pure SaaS isn’t. Labs, sequencing capability, validation, hospital integrations, and clinician adoption all take time and money. A ₹38 crore top-up isn’t just runway. It’s a sign investors were willing to keep financing the infrastructure piece after the initial Series B close.
It also sharpens the company’s strategy. 4baseCare isn’t trying to win by becoming another general AI healthtech story. It’s pairing local testing infrastructure with a data moat built around population-specific clinico-genomic evidence. Then it uses OncoTwin to make that evidence usable for oncologists. That combination — lab network plus decision support — likely appealed to Infosys and growX as repeat backers.
There’s an operational upside for hospitals too. If 4baseCare can push more in-hospital genomics labs instead of forcing samples into faraway reference-lab chains, turnaround times and physician engagement could improve a lot. That’s ambitious, yes. But it’s a more defensible plan than being just another interpretation software vendor.
Why is 4baseCare funding landing in a hot oncology market?
India alone recorded about 1.41 million new cancer cases and 916,827 cancer deaths in 2022, with 5-year prevalence above 3.25 million people. That scale explains why precision oncology isn’t some niche luxury category anymore. The need is already here, especially when treatment decisions increasingly depend on biomarkers, mutation profiles, and resistance patterns rather than organ-of-origin labels alone.
The commercial side is big too. Grand View Research estimates the global precision oncology market at $115.8 billion in 2024 and projects it to reach about $201.96 billion by 2030. IMARC pegs India’s genomics market at $2.5 billion in 2025 and forecasts it at $9.5 billion by 2034. Those are big numbers, sure. But the more useful takeaway is that diagnostics, sequencing, and personalized medicine are attracting real infrastructure capital, not just research interest.
And demand won’t ease. Global cancer cases are projected to rise to 35 million a year by 2050, up from around 20 million in 2022. That’s why investors keep circling oncology even when broader startup sentiment gets shaky. The clinical need is rising, and the data layer in cancer care is still badly underbuilt outside rich healthcare systems.
Final take on 4baseCare funding
The interesting thing about 4baseCare funding isn’t just the ₹128 crore total. It’s that investors are backing a harder model — one that mixes wet-lab execution, hospital partnerships, and AI-driven oncology software in markets that global precision medicine companies have often underserved. The next thing to watch is simple: can 4baseCare turn its current lab footprint and 1,500-test monthly base into a much larger, cross-border genomics network without losing clinical depth or speed?
Read how Coram AI raised a $35M Series B co-led by Ansa Capital and Battery Ventures to turn existing cameras, access systems, and visitor logs into an AI-powered physical security platform that helps teams investigate incidents in plain English.
FAQ
- What is the latest 4baseCare funding round?
4baseCare has closed its Series B at ₹128 crore, including a fresh ₹38 crore top-up led by growX Ventures and Infosys. That came after a ₹90 crore first close backed by Ashish Kacholia, Lashit Sanghvi, and Yali Capital. This round was built in stages rather than in one headline cheque. - How does 4baseCare’s cancer platform work?
It starts with genomic testing from tumor tissue, blood, or both, and then turns that sequencing data into treatment-oriented reports for oncologists. Its SoLiQ approach combines tissue DNA, ctDNA from blood, and germline DNA in one analysis. OncoTwin adds a second layer by matching a patient to similar clinico-genomic cases and summarizing treatment outcomes. - Who founded 4baseCare?
4baseCare was founded by Hitesh Goswami and Kshitij Rishi. Goswami came in with deep genomics and drug-discovery experience, including work at Piramal Life Sciences and a prior genomics IT venture called Bionivid Technology, while Rishi brought strategy, operations, and partnership-building experience from roles at Deloitte and GE. - What market is 4baseCare operating in?
It sits in precision oncology, with one foot in cancer genomics diagnostics and the other in AI-based clinical decision support. That puts it inside two fast-growing categories at once: the global precision oncology market, estimated at $115.8 billion in 2024, and India’s genomics market, estimated at $2.5 billion in 2025.
